Abstract:Abstract Background Bladder cancer (BLCA) is the most common genitourinary tumor but lacks specific diagnostic biomarkers. Recent years have witnessed significant advances in the use and approval of immune checkpoint blockade (ICB) therapy to manage BLCA at advanced stages when platinum-based therapy has failed. The tumor microenvironment (TME) is essential in impacting BLCA patients' prognosis and responsiveness to ICB therapy. CXCL12 is a stromal secreted factor that was essentially involved in regulating the TME among cancers. In this article, we thoroughly investigated the TME regulating roles of CXCL12 in BLCA and revealed its critical involvement in the development of BLCA, which was closely correlated with inflammatory fibroblasts (iCAFs). Methods We examined the gene expression profiles in the TCGA and GEO database to reveal the potential association of CXCL12 with the carcinogenesis and prognosis of BLCA. The receiver operating characteristic curve was used to explore the accuracy of CXCL12 along with multiple iCAFs-associated genes in the diagnosis of BLCA. The MCP-COUNTER, ESTIMATE, and TIDE algorithms were applied to estimate the TME components and predict immunotherapy responsiveness. An iCAFs signature was constructed using the ssGSEA algorithm. The "maftool" R package analyzed the oncogenic mutations in BLCA patients. Bioinformatics analysis results were further validated through immunohistochemistry of clinical samples. IMvigor210 cohort was used to validate bioinformatic predictions of therapeutic responsiveness to immune checkpoint inhibitors. Results This manuscript revealed a significantly reduced expression of CXCL12 in BLCA compared with normal tissue. The expressions of various marker genes for iCAFs were also reduced considerably in BLCA tissues, highlighting the reduction of iCAFs in the pathogenesis of BLCA. Further studies revealed that CXCL12 and iCAFs were associated with pathological features, TME remodeling and aging in BLCA patients. The iCAFs signature further confirmed the intricate immunomodulatory roles of iCAFs in BLCA. Gene mutation analysis revealed the essential relationship between iCAFs and the mutation frequency of oncogenic genes, including TP53 and FGFR3. Meantimes, iCAFs levels also significantly affected BLCA patients' mutations in the TP53 and RTK-RAS pathways. Finally, our results confirmed the significant exclusion of CD8 + T cells by iCAFs, which further influenced the immunotherapy responsiveness in BLCA patients. Conclusions This article highlighted the impact of CXCL12 on the pathogenesis and progression of BLCA. The reduced expression levels of iCAFs markers, including CXCL12, were highly accurate in the diagnosis of BLCA, suggesting the reduction of iCAFs accompanied bladder carcinogenesis. However, both CXCL12 and iCAFs significantly impacted the prognosis and immunotherapy responsiveness for BLCA patients by remodeling the TME. Our results critically suggested the dual roles of iCAFs in the carcinogenesis and progression of BLCA. Further exploration of iCAFs might unravel potential diagnostic biomarkers and therapeutic targets for BLCA.

Expression Of Fas/Fasl And C-Myc In Bladder Cancer And Their Correlation With Tumor Immune Function

Expression of Apoptosiss Correlative Gene Fas,FasL and Bcl-2 in Transitional Cell Carcinoma of Bladder

Fas-mediated Pathway and Apoptosis in Normal Cervix, Cervical Intraepithelial Neoplasia and Cervical Squamous Cancer.

A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer.

Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression

Expression and Prognostic Value of C-Myc and Fas ( CD 95 / APO 1 ) in Patients with Pancreatic Cancer

Fas Ligand Expression in Colon Cancer: A Possible Mechanism of Tumor Immune Privilege

Correlation Between Soluble Fas Level and Apoptosis of T Cells in Ovarian Carcinoma.

A New Strategy to Authenticate Prognosis and Tumor Immunity Model Based on Cancer-Associated Fibroblasts lncRNA in Bladder Cancer

[The Correlation Between DNA Content and Fas Antigen in Non-Small Cell Lung Cancer].

[Expression of Fas, Fas Ligand, Fas-associated Death Domain Protein, Caspase 8 and Mutant P53 Protein in Esophageal Squamous Cell Carcinoma].

Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status

Loss of Fas Expression and High Expression of HLA-E Promoting the Immune Escape of Early Colorectal Cancer Cells.

[Detection of Cell Apoptosis Induced with Anti-Fas Antibody in Bladder Carcinoma Cell Line by Single Cell Gel Electrophoresis].

The cancer‐associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer

Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression

Expression of Fas/Fasl Gene Protein and Its Chinical Significance in Human Non-small Cell Lung Cancer

Altered Expression of Survivin, Fas and FasL Contributed to Cervical Cancer Development and Metastasis.

Activated Cytotoxic Lymphocytes Promote Tumor Progression by Increasing the Ability of 3LL Tumor Cells to Mediate MDSC Chemoattraction Via Fas Signaling.

[Expression of NF-kappa B in Human Bladder Cancer and Its Clinical Significance].

The expression of CXCL5 in bladder cancer and its clinical significance